

NDC	DRUG_PRC	INTRODUCI	WAC_AT_I	MARKETIN	ESTIMATED BREAKTHR	PRIORITY_	ACQUISITIC
62935-046	ELIGARD®	3/8/2023	2710.13	Marketing	144000	ani	No No

ACQUISITIVE GENERAL COMMENTS

As part of Tolmar's commitment to advancing science and patient care, Tolmar has launched

Introducing a new Eligard® (leuprolide acetate) for injectable suspension. The new Eligard is designed to streamline

the mixing and administration process by providing the product in a single, pre-connected unit